Skip to main content

Omega Funds — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

82
Companies
$7.9B
Total invested
$96.5M
Avg. check
26
Industries
Biotechnology 19Health Care 13Therapeutics 8Medical 7Pharmaceutical 6Life Science 4+20 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 82
Eyebiotech
November 2023

Eyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases.

Biotechnology · New York$65.0M Series A
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post-IPO Equity
Kezar Life Sciences
October 2022

Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders

Health Care · South San Francisco$12.2M Post-IPO Equity
Photys Therapeutics
September 2022

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.

Biotechnology · Cambridge$75.0M Series A
GelSight
August 2022

GelSight provides extremely detailed and rapid surface measurements through the novel GelSight sensor technology.

Aerospace · WalthamConvertible Note
etherna immunotherapies
August 2022

etherna develops mRNA and lipid nanoparticle solutions.

Biotechnology · Niel$38.9M Series B
CDR-Life AG
April 2022

CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.

Biotechnology · Schlieren$76.0M Series A
Rectify Pharmaceuticals
October 2021

Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.

Biotechnology · Cambridge$100.0M Series A
Thankful
September 2021

Thankful is a Developer of an automation software created to improve online customer service.

Artificial Intelligence (AI) · Los Angeles$12.0M Series A
Anjarium Biosciences
September 2021

Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.

Biotechnology · Schlieren$60.4M Series A
NeuroVision Imaging
August 2021

NeuroVision Imaging is a developer of digital imaging and diagnostic solutions for Alzheimer's disease.

Biotechnology · SacramentoGrant
Beam Therapeutics
February 2026

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Biotechnology · Cambridge$100.0M Post Ipo Debt
Spruce Biosciences
January 2026

Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.

Biopharma · South San FranciscoPost Ipo Equity
Alveus Therapeutics
January 2026

Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases.

Biotechnology · Philadelphia$197.0M Series A
Alumis
January 2026

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Biotechnology · San Francisco$345.1M Post Ipo Equity
Spiro Medical
January 2026

Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment.

Biotechnology · Menlo Park$67.0M Series A
Kestra Medical Technologies, Inc.
December 2025

Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.

Health Care · Kirkland$138.0M Post Ipo Equity
NRG Therapeutics
September 2025

NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function.

Biopharma · Cambridge$67.8M Series B
BBOT
August 2025

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.

Biopharma · Palo Alto$261.0M Post Ipo Equity
ARTBIO
July 2025

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

Biotechnology · Cambridge$132.0M Series B
Trevi Therapeutics
June 2025

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$115.1M Post Ipo Equity
Senti Biosciences
May 2025

Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for cancer.

Biotechnology · South San Francisco$1.0M Grant
Antares Therapeutics
May 2025

Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.

Biopharma · Boston$177.0M Series A
Nuvation Bio
March 2025

Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.

Biotechnology · New York$150.0M Post Ipo Debt

Where Omega Funds invests

Biotechnology19
Health Care13
Therapeutics8
Medical7
Pharmaceutical6
Life Science4

About Omega Funds's portfolio

How many companies has Omega Funds invested in?▸

Omega Funds has invested in 82 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Omega Funds invest in?▸

Omega Funds's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 26 different industry categories.

What is Omega Funds's largest investment?▸

Among tracked funding rounds, Alumis received $345.1M in a Post Ipo Equity round. Omega Funds's total known invested capital is $7.9B.

What is the average investment size for Omega Funds?▸

Omega Funds's average investment size is $96.5M across its portfolio of 82 companies.

What are Omega Funds's most recent investments?▸

Recent Omega Funds portfolio additions include Eyebiotech, Alpine Immune Sciences, Kezar Life Sciences, Photys Therapeutics, GelSight. These companies were founded in 2020 or later.

Reach the founders behind these 82 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →